Aquestive Therapeutics Gestione
Gestione criteri di controllo 2/4
Aquestive Therapeutics Il CEO è Dan Barber, nominato in May2022, e ha un mandato di 2.5 anni. la retribuzione annua totale è $ 2.50M, composta da 24% di stipendio e 76% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.52% delle azioni della società, per un valore di $ 7.64M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 2.4 anni.
Informazioni chiave
Dan Barber
Amministratore delegato
US$2.5m
Compenso totale
| Percentuale dello stipendio del CEO | 24.0% |
| Mandato del CEO | 2.5yrs |
| Proprietà del CEO | 1.5% |
| Durata media del management | 2.3yrs |
| Durata media del Consiglio di amministrazione | 2.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$600k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$542k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$1m | US$424k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$840k | US$410k | -US$56m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$50m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$1m | US$389k | -US$66m |
| Sep 30 2019 | n/a | n/a | -US$68m |
| Jun 30 2019 | n/a | n/a | -US$64m |
| Mar 31 2019 | n/a | n/a | -US$80m |
| Dec 31 2018 | US$2m | US$319k | -US$61m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$38m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$899k | US$300k | -US$14m |
Compensazione vs Mercato: La retribuzione totale di Dan ($USD 2.50M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.40M ).
Compensazione vs guadagni: La retribuzione di Dan è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Dan Barber (48 yo)
2.5yrs
Mandato
US$2,496,141
Compensazione
Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 7.6m | |
| Chief Financial Officer | 3.9yrs | US$1.12m | 0.43% $ 2.1m | |
| General Counsel | 6.2yrs | US$1.19m | 0.52% $ 2.6m | |
| Chief Operating Officer | 2yrs | Nessun dato | 0.25% $ 1.3m | |
| Chief Innovation & Technology Officer | 9.9yrs | US$810.02k | 1.08% $ 5.4m | |
| Chief Science Officer | no data | Nessun dato | 0.28% $ 1.4m | |
| Senior Vice President of Sales & Marketing | less than a year | Nessun dato | 0.027% $ 138.0k | |
| Senior Vice President of Information Technology & Human Resources | 1.7yrs | Nessun dato | 0.26% $ 1.3m | |
| Chief Medical Officer | no data | Nessun dato | Nessun dato | |
| Chief Medical Officer | 1.4yrs | Nessun dato | 0.28% $ 1.4m | |
| VP of Finance | no data | Nessun dato | Nessun dato |
2.3yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di AQST è considerato esperto (durata media dell'incarico 2.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 7.6m | |
| Independent Director | 8.9yrs | US$202.16k | 0.019% $ 95.7k | |
| Independent Director | 2.3yrs | US$145.23k | 0% $ 0 | |
| Independent Chairman of the Board | 17.7yrs | US$150.77k | 0.082% $ 414.5k | |
| Independent Director | 3.8yrs | US$137.69k | 0% $ 0 | |
| Independent Vice Chairman of the Board | 20.8yrs | US$137.23k | 0.11% $ 549.1k | |
| Independent Director | 3.8yrs | US$121.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.2yrs | Nessun dato | Nessun dato |
2.4yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di AQST non è considerato esperto (durata media del mandato 2.4 anni), il che suggerisce un nuovo consiglio.